RecruitingNot ApplicableNCT06576635

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

LUNG-05: Investigating Chemotherapy Effectiveness for NSCLC Metastatic Patients


Sponsor

University of Illinois at Chicago

Enrollment

29 participants

Start Date

Dec 16, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how well chemotherapy works as a second or later treatment option for people with advanced non-small cell lung cancer (NSCLC) who have already received at least one prior treatment (such as targeted therapy). **You may be eligible if...** - You are 18 years or older - You have been diagnosed with stage IV non-small cell lung cancer confirmed by biopsy - You have already received at least one prior treatment for your lung cancer - You are in good enough health to receive chemotherapy (ECOG performance status 0–2) **You may NOT be eligible if...** - You have not yet received any prior treatment for your lung cancer - Your health is too poor to tolerate chemotherapy - You have active brain metastases that are untreated Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDocetaxel

75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle

DRUGPaclitaxel

135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle

DRUGGemcitabine

1000 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1,250 mg/m2 IV over 30 minutes on Days 1 and 8 of each 21 day cycle

DRUGPemetrexed

500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle

DRUGVinorelbine

30 mg/m2 IV through a weekly injection over 6-19 minutes on Days 1, 8, and 15 of each 21-day cycle


Locations(1)

University of Illinois Cancer Center

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06576635


Related Trials